Analysis of Beijing Balance Medical's Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach - aVenture Research
Insight, China's Pharmaceutical Industry
Beijing Balance Medical's Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach
Beijing Balance Medical Technology Co., Ltd (SHA: 688198) announced that its independently developed transcatheter pulmonary valve system has been approved for market launch by China's National Medical Products Administration (NMPA) – the company's third interventional valve product cleared through the NMPA Special Review Procedure for Innovative Medical Devices, designed to meet the clinical needs of a broad spectrum of patients requiring transcatheter pulmonary valve replacement (TPVR).
An analysis reads this article and its sources, then explains what happened, who is involved, and what it means, quoting a source for each claim. Once written, every reader sees it here.
Analysis requires a paid plan or prepaid credits and uses your company research allowance.